September medical events list: unicorns, private top 500 enterprises are concerned

"Pharmaceutical Network Industry Dynamics" In September, what new lists were released for the pharmaceutical industry? According to the author combing, pharmaceutical companies for "2019 China's potential unicorn enterprises list", "2020 China's top 500 private enterprises" and other lists of the hot heat, in addition to related drug sales, pharmaceutical companies market value ranking changes have also attracted the attention of the industry.
2019 county-level public hospital best-selling varieties list recently, 2019 county-level public hospitals best-selling varieties list released.
among them, the top 10 chemical markets are: sodium chloride, atovastatin, clopidogre, human haemoglobin, omeprazole, pyridoxine, mendon insulin, low molecular heparin, vitolaze, entikave.
its sales are more than 260,000 yuan ( million yuan) in the Chinese medicinal market, the top 10 are: thrombosis, thrombosis, thrombosis, Danhong, dansan polyphenolates, magpie flat, wake-up, tesame, ginseng wheat, sorghum yellow.
its sales are more than 77,000 yuan (10,000 yuan).
48 biopharmaceutical companies were listed on the 2019 List of China's Potential Unicorn Enterprises on September 3rd, and the 2020 China Potential Unicorn Enterprise Research Report was successfully announced.
report shows that in 2019, There are 296 potential unicorn enterprises in China, distributed in commercial aerospace, VR/AR, high-end intelligent equipment, biomedicine and other tracks, mainly concentrated in the "North, Shanghai, Hangzhou, Shenzhen" four cities, and more than half are located in the national high-speed zone.
In the field of biomedicine, according to the author combing, including No cheng Jianhua, Kangfang Biological, Peijia Medical, stone-burning medicine, Ebonod, Pharmaceutical Ming Juno, Hai and Biology, Novzan Bio, Kanga Technology, Olin Biology, Six Heningyuan, Yi TengjingAng, Yidi and other at least 48 biopharmaceutical companies on the list.
the second quarter of 2020, GlobalData, a data analytics and consulting firm, released data on the market capitalization rankings and changes of the top 20 innovative pharmaceutical companies in the second quarter of 2020.
market capitalisation of the world's top 20 pharmaceutical companies rose 10.2 per cent to about $2.8 trillion in the second quarter, a marked rebound from the first quarter.
, the top five companies by market capitalisation remained unchanged from the first quarter, followed by Johnson and Johnson, Roche, Novar3, Merck and Pfizer.
the top ten best-selling drugs in 2019, Informa, a global pharmaceutical information consulting platform, summarized the top 10 best-selling drugs in 2019.
that the total sales of the top 10 best-selling drugs amounted to $92.5 billion.
, the top ten were Adamo single resistance, Pim single resistance, lenadomide, Erudini, Navu single resistance, Apixaban, Apasip, Inasip, Beval single resistance, lyxi monoanti.
12 pharmaceutical companies were shortlisted for the 2020 China Private Enterprise 500 on September 10, 2020 China's top 500 private enterprises summit held in Beijing, the meeting unveiled the "China's top 500 private enterprises" "China's private enterprise manufacturing 500" "China's private enterprise services top 100" three lists.
from the 2020 China's top 500 private enterprises, according to the author combing, in the field of pharmaceutical manufacturing, there are 12 shortlisted enterprises, including Yangzijiang Pharmaceuticals (71), Correctional Pharmaceuticals (124), Hai wang Group (131), Vico Group (165), Colum Pharmaceuticals (213), Shipharma Holdings (247), East China Pharmaceuticals (259), Wuhan Contemporary Science and Technology (312), Tian Shili (329), Jimin Credibility (365), Changjiang Runfa Group (414), Hengrui Pharmaceuticals (424).